Clinical Trials
Have You Considered Participating in a Clinical Trial?
There are several benefits to participating in a clinical trial, including:
- Access to Cutting-Edge Treatments – Clinical trials offer the opportunity to receive innovative therapies before they become widely available.
- Personalized Care – Participants receive close monitoring and specialized care from leading medical professionals.
- Advancing Research – Your participation helps drive progress in breast cancer treatment, potentially benefiting future patients.
- Expanded Treatment Options – Trials may provide access to new drugs or combinations that could be more effective than standard treatments.
- Hope for Better Outcomes – Experimental treatments in trials may offer improved survival rates or better quality of life.
- Contributing to Scientific Knowledge – Your involvement helps researchers understand breast cancer better, leading to more targeted and effective therapies.
- Potential Cost Savings – Many trials cover the cost of study-related treatments, reducing financial burdens for participants.
Clinical Trial Conversations
Clinical trials play a vital role in advancing cancer treatment and improving patient outcomes. Join our expert panel for an in-depth discussion on how clinical trials work, what participation involves, and how they contribute to the future of cancer care.
Educational campaign sponsored by
Hear What Our Community is Saying About Clinical Trials
Dear Sue & the Unite for HER Team,
Thank you for shining a light on the power of clinical trials — I can personally attest to the life-changing benefits.
I’m a proud participant in the I-SPY 2 clinical trial at NYU Perlmutter, and it has completely reshaped my experience with breast cancer care. As a woman of color, I know the hesitation — our history includes painful truths like Henrietta Lacks, whose cells were used without permission. That legacy breeds fear, but my journey has been one of empowerment and trust.
The I-SPY program provides extraordinary care — enhanced scans, personalized treatment, dedicated nurse navigators, and a true sense of partnership in healing. Layered on top of that, the Unite for HER support has been a lifeline. Through my HER Passport, I’ve benefited from the dietitian consultations, Cassandra’s incredible group support (she’s a gem 💕), and those grocery gift cards that helped offset the cost of pricey meds — a true blessing.
Together, I-SPY and Unite for HER have created a healing ecosystem rooted in compassion, innovation, and sisterhood. If my story inspires even one person to say yes to a clinical trial or seek support, then I’ve done my part — out loud and on purpose.
With deep gratitude and love,
Tei
New Clinical Trial Opportunities
Please verify with your physician to see if these opportunities are the right fit for you. Must be 18 years or older to apply. Click below to find the latest information on available clinical trials by diagnosis.
Early Breast Cancer
Please stay tuned for additional details regarding trials are currently available for patients diagnosed with Early Breast Cancer.
Phase IIIb Study of Ribociclib + Endocrine Therapy (ET) in Early Breast Cancer (Adjuvant WIDER) Novartis Study
Who can participate:
- Adults (18+) with early-stage, ER+, HER2-negative breast cancer
- Cancer has been completely removed by surgery (Stage III, IIB, or some IIA)
- Currently on endocrine therapy (Started within the last 36 months; At least 3 years of treatment remaining; Able to manage daily activities independently)
- Radiation before or after surgery is allowed
Who cannot participate:
- Cancer has spread beyond nearby lymph nodes or has returned
- Have already completed most endocrine therapy or started it too long ago
- Have serious uncontrolled health conditions
- Are pregnant, breastfeeding, or not using birth control (if applicable)
Contact Information:
- Novartis Pharmaceuticals (General Contact):
- International: +41 61 324 1111
- U.S.: 1-888-669-6682
- novartis.com/clinicaltrials/study/nct05827081
Triple Negative Breast Cancer
Please stay tuned for additional details regarding trials are currently available for patients diagnosed with Triple Negative Breast Cancer.
Metastatic Breast Cancer
The following trials are currently available for patients diagnosed with Metastatic Breast Cancer:
INAVO123
Genentech Study #WO45654
- This clinical trial is evaluating inavolisib in combination with a targeted therapy (CDK4/6i) and letrozole compared with a placebo plus CDK4/6i and letrozole in the first-line setting for patients with specific characteristics.
- The study population includes people with endocrine-sensitive PIK3CA-mutated HR+, HER2-, advanced breast cancer.
- The study is open at 10 sites across the country, with plans to open more than 30 additional sites soon.
For more information please call 888-662-6728 (U.S. only, Monday – Friday, 5am – 5pm PT) or email global-roche-genentech-trials@gene.com.
Click the blue button below to Chat (Monday – Friday, 5am – 5pm PT)
pionERA Breast Cancer
Genentech Study # CO44657
- This clinical trial is comparing giredestrant with fulvestrant, both combined with a targeted therapy (CDK4/6 inhibitor – either palbociclib, ribociclib, or abemaciclib).
- The study population includes people with ER+, HER2- breast cancer that has come back after adjuvant hormone therapy.
- This study is currently open at 53 clinical sites in the United States.
For more information please call 888-662-6728 (U.S. only, Monday – Friday, 5am – 5pm PT) or email global-roche-genentech-trials@gene.com.
Click the blue button below to Chat (Monday – Friday, 5am – 5pm PT)
MoonROSE
Genentech Study #GO46021
This clinical trial is evaluating GDC-4198, a novel oral CDK4/2 inhibitor, administered alone y and in combination with Giredestrant in comparison with Abemaciclib and Giredestrant.The study population includes people with locally advanced or metastatic estrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer who have progressed during or after treatment with a CDK4/6 inhibitor.
This is a Phase Ib/II study designed to evaluate the safety, pharmacokinetics, and activity of this new targeted therapy.
The study is open at 11 clinical sites in the United States, with plans to open additional 24 sites soon.
For more information please call 888-662-6728 (U.S. only, Monday – Friday, 5am – 5pm PT) or email global-roche-genentech-trials@gene.com.
Genentech BREnnA
Study #WO46069
- This clinical trial is studying an investigational oral medication (a targeted treatment known as a tyrosine kinase inhibitor, or TKI) in combination with standard HER2-directed therapies for adults with HER2-positive metastatic breast cancer.
- The study is enrolling adults whose breast cancer has spread and who have previously received HER2-targeted treatment. People may be eligible if they received a HER2 TKI in the early-stage setting (before or after surgery) as long as treatment was completed at least 12 months ago. However, people who have received a HER2 TKI for locally advanced or metastatic breast cancer are not eligible.
- The study is planned to open at approximately 80 sites across the United States. Enrollment is expected to begin in May 2026.
DV-006
Pfizer Study #C5731006
- DV-006 is a clinical trial evaluating a study medicine, disitamab vedotin (DV), for people with HER2-expressing advanced breast cancer that has worsened after prior treatment.
- Disitamab vedotin (DV) is an antibody-drug conjugate (ADC). It is thought to work by sticking to and killing cancer cells that make HER2.
- The study population includes adults (women and men) with locally advanced unresectable or metastatic HER2-expressing breast cancer.
- The study will be open at 25 sites across the country.
- If you or a loved one is interested in participating, please visit the study website for more details.
KATSIS-1
Pfizer Study #C4551002
- KATSIS-1 is a clinical trial evaluating prifetrastat in combination with fulvestrant, compared with 1 of 2 currently approved treatments (either exemestane or fulvestrant) chosen by the study doctor, plus an approved medicine called everolimus, for patients with advanced or metastatic breast cancer.
- The study population includes adults (women and men) with hormone receptor-positive (HR+), HER2-negative advanced breast cancer.
- Participants have received certain 2 or less previous treatments for their advanced or metastatic breast cancer, as well as treatment with a CDK4/6 inhibitor, such as palbociclib (Ibrance®), ribociclib (Kisqali®), or abemaciclib (Verzenio®)
- The study is currently open at about 48 sites across the United States, with hundreds of other sites open globally.
- If you or a loved one is interested in participating, please visit the study website for more details.
Phase I/II Trial of ECI830 as Monotherapy and in Combination with Ribociclib + Fulvestrant in HR+/HER2- Advanced Breast Cancer and Other Solid Tumors
Novartis Study
You may qualify if you:
- Are 18 years or older.
- Have advanced HR+/HER2- breast cancer that progressed after prior CDK4/6 inhibitor and hormone-based therapy, plus at least one additional advanced-line treatment.
- Have not previously received a CDK2 inhibitor.
- OR have another advanced cancer with confirmed CCNE1 (cyclin E1) amplification.
- Have at least one measurable tumor on imaging (including trackable bone lesions for breast cancer).
- Are able to perform daily activities independently.
- Do not have active or untreated brain metastases.
- Do not have serious uncontrolled heart conditions or poor bone marrow/organ function.
- Are not pregnant or breastfeeding and are willing to use effective birth control.
- Have not previously been unable to tolerate ribociclib or other protocol-restricted treatments.
Participation is voluntary. You may withdraw at any time by notifying the study team, who will guide medication discontinuation and follow-up care.
Phase Ib Study of [177Lu]Lu-NeoB with Ribociclib + Fulvestrant in ER+/HER2-/GRPR+ Advanced Breast Cancer (NeoB-LEE1)
Novartis Study
You may qualify if you:
- Are an adult with advanced or metastatic ER+/HER2- breast cancer.
- Developed metastasis during or within one year of completing (neo)adjuvant hormone therapy.
- OR had disease progression on first-line hormone therapy with a CDK4/6 inhibitor for metastatic disease.
- May have treated brain metastases if stable, completed radiation/surgery ≥4 weeks ago, and not requiring steroids or anti-seizure medications.
- Have not previously received fulvestrant.
- Have had no more than one prior treatment for advanced disease.
- Did not require ribociclib dose reduction for safety reasons.
- Do not have inflammatory breast cancer, serious heart disease, or advanced liver cirrhosis.
- Are not allergic to study drugs and have not had recent pancreatitis.
- Are not taking restricted medications (e.g., warfarin, certain heart/liver-interacting drugs) or consuming contraindicated foods (e.g., grapefruit).
Ovarian Cancer
Please stay tuned for additional details regarding trials are currently available for patients diagnosed with Ovarian Cancer.
Trusted Nonprofit Partners
Please contact them directly to learn about the clinical trials featured on their websites below.
When We Tri(al) is a special initiative by TOUCH:The Black Breast Cancer Alliance to provide Breasties, caregivers, and the entire Black community with an easy way to search and match to breast cancer clinical trials.
BreastCancerTrials.org is a free, patient-friendly, non-profit clinical trial matching service that helps people with any stage of breast cancer learn about and find clinical trials that are right for them, with over 700 active clinical trials listed.
Metastatic Trial Search is a free, patient-friendly, non-profit clinical trial matching service designed specifically for people with metastatic breast cancer
If you are interested in speaking with someone who has participated in a cancer-related clinical trial, register to speak to a Mentor Angel through Imerman Angels. If you have participated in a cancer-related clinical trial and would like to help someone else through their experience, please register to become a Mentor Angel.
Metastatic Trial Talk is a monthly newsletter published by BreastCancerTrials.org featuring different topics, research data, and new clinical trials.